AustriaAustria

Spotlight on new EU Members

10.07.2004

Vienna - “Cautious optimism, but still a long way to go” - this was the common theme of three life science experts from the Czech Republic, Slovakia and Hungary at the welcoming symposium “Spotlight on Life Sciences in Central Europe” in Vienna. The event was organized for these new EU member states by Life Science Austria Vienna Region. Ernö Duda, founder and owner of Hungary's successful biotech company Solvo Biotechnology Inc. and chairman of the Hungarian Biotechnology Association, named his country's biggest obstacle to enhanced growth in the biotech sector the “lack of capital and managerial expertise”. Yet more important than lacking capital is the absence of managerial expertise amongst scientists. “I can still count the scientists in Hungary that hold an additional degree in law or an MBA with the fingers of one hand”. A friend of his in Hungary who “is an outstanding researcher, trained in the UK and the USA working in the field of central nervous disease - a multibillion dollar business” never thought about filing a patent to protect or commercialize his research results.
Low awareness of researchers towards commercialization of their scientific discoveries was a point raised by Jiri Vanecek, Czech Academy of Sciences, and Jan Turna, Comenius University, Bratislava. However, becoming a member of the EU earlier this year paved the way for harmonized intellectual property standards in all three countries. Duda and Vanecek agreed on the high level of university education in their countries. Especially Hungarian scientists have an impressive record of papers in high impact journals. However, all complained that too many of them leave their home countries in pursuit of better opportunities in the USA. “To get just five of the brightest of these scientists back to Hungary would boost the sector enormously. But that would also mean for the government a stronger commitment to provide incentives to lure these people back to Hungary,” said Duda.
Despite notoriously low government spending for the biotech sector all three countries have developed fields of expertise. Vanecek referred to the pioneering work of the Dr. Antonin Holy, the first to synthesize several nucleotide derivatives for the treatment of AIDS and hepatitis B, currently marketed by US biotech giant Gilead. Both in the Czech Republic and in Slovakia industries with low added value, including classical fermentation and manufacturers of generics dominate.
One of Slovakia's success stories is Biotika AS, which soon emerged as a leading producer of the essential amino acid L-Lysine after the founding in 1953. Yet “frequent change in government attitudes towards biotechnology is still a big obstacle and so far the government has paid only lip service to support small and medium enterprises,” Turna said. But despite much criticism all three countries do have examples of successful biotechs like Slovakia's Danubeclone SRO, which focuses on the production of monoclonal antibodies, Czech Apronics developing bioactive recombinant proteins, and Hungarian ComGenex Inc., specialised on ways to speed up drug discovery. Eventually Turna found conciliating words when he stressed his country's “appropriate research in biotechnology and significant interest of young people to study and work in the field.”
Author/Contact
Dr. Martin Spatz, Life Science Austria Vienna
Region, Vienna, eMail: spatz@lifescienceaustria.at

AustriaAustria

09.03.2012

Breast cancer patients who receive radiation therapy often suffer from inflammation linked to the treatment. Austrian Apeiron Biologics AG is now developing a topical superoxide dismutase treatment (APN201) to try to help these...

AustriaAustria

06.03.2012

The Paracelsus Private Medical University (PMU) in Salzburg is to build a new research center for spinal cord injuries. The €70m construction tab will be picked up by Dietrich Mateschitz, the owner of Red Bull. Other partners in...

AustriaAustria

16.12.2011

Vienna – Two big investors have poured €25m into Austrian vaccine specialist Affiris AG. Venture fund Santo VC – the investment vehicle of German biotech investors Thomas and Andreas Strüngmann – donated €20m, while the German...

AustriaAustria

08.11.2011

Vienna – In Affiris they trust – as a proof of their faith, two big investors poured €25 million into the Austrian developer of a possible Alzheimer drug. Venture fonds Santo VC, the investment vehicle of the German billionaires...

AustriaAustria

17.08.2011

Innsbruck – Austrian specialist for so-called ugimeres, Ugichem GmbH, has landed fresh funding. Along with V+ GmbH and the Austrian Research Promotion Agency, Swiss private investors invested about EUR2m to develop the first...

AustriaAustria

12.08.2011

Innsbruck – An Austrian physician has been fined EUR4,500 in a case involving a controversial stem cell therapy for incontinence. In early August, an Innsbruck Regional Court adjudged Hannes Strasser, who developed the method, at...

AustriaAustria

11.06.2011

Vienna – Nabriva Therapeutics AG, an Austrian specialist for the development of novel antibiotics, has achieved proof-of-concept for its first product in a clinical Phase II study. Called BC-3781, the compound is used to treat...

AustriaAustria

11.06.2011

Vienna – Nabriva Therapeutics AG, an Austrian specialist for the development of novel antibiotics, has achieved proof-of-concept for its first product in a clinical Phase II study. Called BC-3781, the compound is used to treat...

AustriaAustria

28.04.2011

Vienna - f-star, an antibody specialist, today announced the closing of aEUR 15 Million financing. The investment was led by SR One, the corporate venture capital arm of GlaxoSmithKline. All of f-star’s existing investors, Atlas...

Displaying results 1 to 10 out of 116

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-austria/article/spotlight-on-new-eu-members.html

Print Magazine

Product of the week

Products

Events

All Events

Stock list

All quotes

TOP

  • CO.DON2.65 EUR6.00%
  • FORMYCON10.90 EUR4.51%
  • CYTOS0.29 CHF3.57%

FLOP

  • BIOTEST79.48 EUR-2.68%
  • ADDEX2.99 CHF-1.97%
  • EVOTEC3.23 EUR-1.22%

TOP

  • CYTOS0.29 CHF70.6%
  • FORMYCON10.90 EUR38.1%
  • EPIGENOMICS5.16 EUR35.8%

FLOP

  • 4SC0.90 EUR-15.1%
  • CO.DON2.65 EUR-9.6%
  • BIOFRONTERA2.59 EUR-9.4%

TOP

  • SANTHERA92.95 CHF2346.1%
  • CO.DON2.65 EUR165.0%
  • BB BIOTECH183.40 EUR61.4%

FLOP

  • CYTOS0.29 CHF-91.3%
  • 4SC0.90 EUR-49.4%
  • THERAMETRICS0.07 CHF-46.2%

No liability assumed, Date: 26.11.2014

Current issue

All issues